Bill Text — Oct 4, 2012
This bill’s text is now available.
Sep 21, 2012
112th Congress, 2011–2013
This bill was introduced on September 21, 2012, in a previous session of Congress, but was not enacted.
Representative for California's 50th congressional district
Read Text »
Last Updated: Sep 21, 2012
Length: 13 pages
To amend title V of the Federal Food, Drug, and Cosmetic Act to provide for extensions of marketing exclusivity periods for drugs in certain combinations of such drugs, and for other purposes.
The “H.R.” in “H.R. 6502” means this is a House of Representatives bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
Search for similar bills.
Click a format for a citation suggestion:
Civic Impulse. (2015). H.R. 6502 — 112th Congress: Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/hr6502
“H.R. 6502 — 112th Congress: Life-Threatening Diseases Compassion through Combination Therapy Act of 2012.” www.GovTrack.us. 2012. July 8, 2015 <https://www.govtrack.us/congress/bills/112/hr6502>
|title=H.R. 6502 (112th)
|accessdate=July 8, 2015
|author=112th Congress (2012)
|date=September 21, 2012
|quote=Life-Threatening Diseases Compassion through Combination Therapy Act of 2012